Roger Jelliffe MD1, Alan Schumitzky PhD1,2, David Bayard PhD1,3, Robert Leary1,4, PhD, Alison Thomson PhD5, Andreas Botnen, MS1, Maurice Khayat BS1, Michael Neely MD1 Optimal Stochastic Control Of Drug Dosage Regimens
|
R.R. Press(1,2), H.H. van Rossum(3), B.A. Ploeger(4,5), J. den Hartigh(1), J. van Pelt(3), H.-J. Guchelaar(1), J.W. de Fijter(2) and M. Danhof(4,5) Is Calcineurin Activity Useful as a Biomarker to Optimize Cyclosporine A Therapy in Renal Transplant Recipients?
|
Helene Karcher (1), Ken Abrams (2), Alan Slade (2), Olivier Luttringer (1) Interpreting QT in a Patient Population After Surgical Intervention
|
Gregory Pinault, Aurelie Gautier, Goonaseelan Pillai, Jean-Louis Steimer, Vincent Buchheit Quality, Efficiency and Industrialisation Initiatives during the evolution of a dedicated SAS Programming Group
|
N. Snelder (2), T. van Steeg (2), B. Ploeger (2), N. Attkins (1), P. van der Graaf (1) Safety pharmacology screening using a standardized population pharmacokinetic pharmacodynamic modelling approach
|
C. Ambery(1), M. Beerahee(1) Population PK-PD Modelling of Wheal and Flare Area in a First-Time-in-Human Study
|
Thaddeus Grasela* (1), Jill Fiedler-Kelly (1), Darcy Hitchcock (1) Improving the Efficiency and Ensuring the Quality of Data Assembly for Pharmacometric Analysis
|
D.S. Bordin, T.S. Kozhurina, S.Yu. Silvestrova, V.N. Drozdov, E.R. Valitova, A.A. Masharova, A.V. Petrakov Relating Pharmacokinetics and Pharmacodynamics of Proton Pomp Inhibitors (PPIs) to Clinical Performance in Patients with Gastroesophageal Reflux Disease (GERD)
|
Guangli Ma1, Bo L Olsson2, Johan Rosenborg2, Mats O. Karlsson1 Quantifying Lung Function Progression in Asthma
|
Andreas Kuttler (1), Thomas Dimke (1), Ramprasad Ramakrishna (2), Gabriel Helmlinger (2), Anne Ruehl (2), Marie-Laure Rouzade-Dominguez(2), Gervais Tougas (2), Mark Fox (3), Werner Schwizer (3) A 3D mechanical model of the gastric esophageal junction: model-based assessment of muscle stretch tension in the gastric smooth muscle with emphasis to reflux disease
|
Nicolás J (1), Oltra D (2), Navarro-Fontestad C (2), Nicolás N (3), Ramírez F (4), Alós M (5), Casabo VG (2) Population pharmacokinetics of Ropivacaine and Bupivacaine after loco-regional administration as anesthetic in hip or knee replacement surgery.
|
Joseph F Standing (1), Marie Sandström (2), Tommy Andersson (2), Kerstin Röhss (2), Mats O Karlsson (1) Population Pharmacokinetic Modelling of Esomeprazole Nonlinearity
|
I. Locatelli (1), B. Perissutti (2), D Voinovich (2), A. Mrhar (1), I. Grabnar (1) Population Pharmacokinetic Analysis of Silymarin Bioavailability in Rats
|
Ines Paule (1), Hind Sassi (2), Anoosha Habibi (3), Dora Bachir (3), Frédéric Galactéros (3), Pascal Girard (1), Anne Hulin (2), Michel Tod (1, 4) Population Pharmacokinetics and Pharmacodynamics of Hydroxyurea in Sickle Cell Anemia Patients, In Silico Comparison of Two Dosing Regimens
|
I. Grabnar (1), T. Trdan (1), P. Bohanec Grabar (2), B. Rozman (3), D. Logar (3), M. Tomsic (3), D. Suput (3), L. Peterlin Masic (1), V. Dolzan (2), A. Mrhar (1) Population Pharmacokinetics of the Active Metabolite of Leflunomide in Patients with Rheumatoid Arthritis
|
Flora Tshinanu Musuamba (1), Michel Mourad (2), Vincent Haufroid (3), Roger K. Verbeeck (1) and Pierre Wallemacq (3). Time of Drug Administration, Genetic Polymorphism and Analytical Method Influence Tacrolimus Pharmacokinetics: A Population Pharmacokinetic Approach
|
C. van Kesteren1, M.A. Boroujerdi1, A. Roy1, A. Facius2, M. Danhof1, O.E. Della Pasqua1,3 Prediction of drug effects using a longitudinal turnover model for FEV1 in patients with chronic obstructive pulmonary disease (COPD).
|
N.H. Prins (1), M. Green (1), S. Haughie (2), P. Johnson (2), S. W. Martin (2) Use of model based meta-analysis combining patient-level with summary-level data using multilevel random effects to provide a quantitative assessment of the clinical efficacy (IPSS) profile and competitive positioning of a PDE5 inhibitor (UK369,003) for the treatment of benign prostatic hyperplasia (BPH).
|
Jonathan L. French (1), Neal Thomas (2), Sriram Krishnaswami (3), Gary Chan (4) Safety monitoring of a kidney transplant study using a Bayesian time-to-event model
|
KT. Baron, AK. Birnbaum, JC. Cloyd, J. St. Peter, and RC. Brundage Evaluation of Assumptions in the Clinical Use of the Cockcroft-Gault Equation
|
Martin Bergstrand (1), Sandra Visser (2), Catharina Alm (1), Ahmad Al-Saffar (3), Mats O Karlsson (1) Semi-mechanistic PK/PD modeling of Paracetamol and Sulfapyridine to characterize effects on gastric emptying and small intestinal transit
|
Jason H. Williams (1), Bhuvaneswari Jayaraman (1), Richard S. Finkel (2), Jeffrey S. Barrett (1) Bayesian Network Approach to Modeling Spinal Muscular Atrophy Populations
|
Musuamba F(1), Mourad M(2), Haufroid V(3), Wallemacq P(4), Verbeeck RK(1) Multivariate and Population Pharmacokinetic Analyses for Tacrolimus Area Under The Concentration-Time Curve Prediction in De Novo Renal Transplant Recipients
|
L. Liefaard (1), D. Huntjens (2), A. Vermeulen (2) & H. Drenth (1) Modelling non-linear dose-dependent absorption profiles after oral prolonged release formulations
|
P. Johnson (1), S. W. Martin (1), P. Milligan (1), A. Cleeton (2), A. Heatherington (2), A. Crossland (3), S. Haughie (3), J. Lamb (4), N. Tamimi (4) & N.H. Prins (5). Enhanced quantitative drug development (EQDD) of a selective PDE5 inhibitor for the treatment of benign prostatic hyperplasia (BPH)
|
Sven Mensing, Peter Nörtersheuser, Paul-Matthias Diderichsen Markov Modeling of Side Effect Related Dropout Rates by Introduction of Previous State Memory
|